Cardiology Self-Assessment Program (CardSAP) Book 2: Arrhythmias and Thrombosis (Cert # L249250)

The target audience for Cardiology Self-Assessment Program (CardSAP) Book 2: Arrhythmias and is board-certified and advanced level cardiology clinical pharmacists.

Board-certified pharmacists are eligible to receive up to 21.5 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.   

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.

ACCP and ASHP are approved by BPS as a provider for the recertification of BCCP .

Arrhythmias and Thrombosis I
ACPE #: 0217-9999-24-225-H01-P
Chapter: ECG Interpretation of QT Prolongation

• Justify the pharmacist’s role in interpreting ECGs.
• Evaluate and interpret normal and abnormal waveforms and intervals on an ECG.
• Measure and calculate the QT/corrected QT (QTc) interval using a 12-lead ECG.
• Given a patient case and 12-lead ECG, analyze factors that influence the accuracy and reliability of the heart rate QTc.
• Given a patient case, analyze risk factors for QT prolongation.
• Given a patient case, provide recommendations for the management of QT prolongation. 

Case Series: Atrial Fibrillation Clinics

• Justify the role of the pharmacist in the multidisciplinary team-based care for patients with atrial fibrillation.
• Apply optimization of antiarrhythmic medication therapy management based on patient-specific factors.
• Apply optimization of anticoagulant medication therapy management based on patient-specific factors.
• Apply comprehensive medication management strategies to provide individualized care of patients with atrial fibrillation. 

Arrhythmias and Thrombosis II
ACPE #: 0217-9999-24-226-H01-P
Chapter: Ventricular Tachycardia

• Identify the mechanism and type of ventricular tachycardias (VTs).
• Recommend treatment options for the acute management of ventricular tachycardia.
• Evaluate treatment options for the long-term management of ventricular tachycardia.
• Distinguish the characteristics of select rare VT conditions and commonly used medical therapy. 

Chapter: Antiarrhythmic Medications vs. Ablation

• Distinguish patients who are ideal candidates for early rhythm control.
• Evaluate the risks and benefits of strategies to maintain normal sinus rhythm in patients with atrial fibrillation.
• Develop a treatment plan for a patient who has undergone surgical or catheter ablation. 

Arrhythmias and Thrombosis III
ACPE #: 0217-9999-24-227-H01-P
Chapter: Cardiac Wearables and Self-Monitoring Devices

• Identify available cardiac devices and sensors and the roles they play in preventing and/or managing cardiovascular disease states.
• Evaluate clinical outcomes and treatment implications of cardiac wearables when screening for or managing preexisting atrial fibrillation.
• Distinguish benefits and challenges with direct-to-consumer cardiac wearables.
• Justify the role of home international normalized ratio monitoring for patients on chronic warfarin therapy. 

Chapter: Risk Modification for Atrial Fibrillation

• Distinguish the differences between the lifestyle and risk factor modification (LRFM) recommendations of the previous and current atrial fibrillation (AF) guidelines.
• Assess the risk for developing AF based on current modifiable and nonmodifiable risk factors.
• Detect the presence of AF based on clinical evaluation and available screening tools.
• Design an appropriate LRFM care plan when treating patients at risk for or diagnosed with AF.
• Evaluate the risk for stroke and bleeding in patients with AF using validated risk stratification tools.

Arrhythmias and Thrombosis IV
ACPE #: 0217-9999-24-228-H01-P
Chapter: Antithrombotic Therapy for Valvular Heart Disease

• Analyze the associated thrombotic risks associated with valvular heart disease (VHD) repair and replacement options.
• Develop a pharmacologic treatment plan for a variety of patient subsets and situations after VHD correction interventions that optimizes the use of guideline-directed medical therapy.
• Justify the pharmacist’s role in anticoagulation stewardship in patients with VHD. 

Arrhythmias and Thrombosis V
ACPE #: 0217-9999-24-229-H01-P
Case Series: Left Ventricular Thrombus

• Assess risk factors for developing left ventricular (LV) thrombus.
• Develop a patient care plan for preventing or treating LV thrombus.
• Evaluate the use of a direct oral anticoagulant compared with warfarin in the treatment of LV thrombus.
• Analyze the role of dual antiplatelet therapy and fibrinolytics for the treatment and prevention of LV thrombus. 

Recorded Webcast: Management of Supraventricular Tachycardias

• Distinguish between the various dysrhythmias that are classified as supraventricular tachycardias (SVTs).
• Determine available pharmacologic agents for treating patients with SVT.
• Develop individualized treatment plans for patients with SVT.

Faculty Information

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ACCP and ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships: 

Consultancies: Anastasia L. Armbruster (American College of Cardiology/American Heart Association Joint Committee for Clinical Practice Guidelines); Kristen Bova Campbell (Wolters Kluwer, Heart Rhythm Society); James C. Coons (AstraZeneca, Merck, Pfizer-Bristol Myers Squibb Alliance); Paul P. Dobesh (Pfizer/BMS Alliance, Janssen); John Lindsley (Lexidrug); Kelly M. Rudd (Wolters Kluwer, American Heart Association, Anticoagulation Forum); Amanda Winans (Bristol Myers Squibb)

Grants: James C. Coons (Heart Rhythm Society); James D. Hoehns (Lilly [two grants], Novartis); Kelly M. Rudd (Pfizer [Global Medical Grants & Partnerships])

ACCP Staff/Series Leaders
Consultancies: Cynthia Jackevicius (AHA, CSHP)

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

• Complete the attestation statement
• Review all content
• Complete and pass the assessments
• Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

ACCP and ASHP collaborate on cardiology pharmacy activities.